2018
Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial
Tan W, Panchal A, Buckley L, Devall A, Loubière L, Pope A, Feneley M, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths T, Page T, Hodgson D, Datta S, Billingham L, Kelly J. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. European Urology 2018, 75: 63-71. PMID: 30274699, DOI: 10.1016/j.eururo.2018.09.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerDisease-free survival timeCarcinoma in situBacillus Calmette-GuerinSecond-line therapyTreatment armsComplete responseOpen-labelNo significant differenceBladder cancerCourse of bacillus Calmette-GuerinNon-muscle-invasive bladder cancer patientsBacillus Calmette-Guerin failuresCarcinoma in situ patientsStandard second-line therapyBacillus Calmette-Guerin therapyRecurrence of non-muscle-invasive bladder cancerStandard of care treatmentControlled trialsPapillary bladder lesionsPhase III randomised controlled trialMedian follow-upBladder cancer outcomesSignificant differenceOutcome measuresIntravesical device-assisted therapies for non-muscle-invasive bladder cancer
Tan W, Kelly J. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nature Reviews Urology 2018, 15: 667-685. PMID: 30254383, DOI: 10.1038/s41585-018-0092-z.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerElectromotive drug administrationDevice-assisted therapiesBladder cancerHyperthermic chemotherapyDevice-assisted treatmentsIntravesical adjuvant treatmentHigh-risk diseaseResults of randomized trialsRisk of recurrenceRisk of progressionAlternative to BCGEffective treatment optionSingle-arm study designBladder cancer diagnosisBCG failureRandomized controlled trialsMaintenance regimensAdjuvant treatmentPatient cohortTreatment optionsRandomized trialsDrug AdministrationControlled trialsClinical guidelines
2014
Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice
Tan W, Lamb B, Payne H, Hughes S, Green J, Lane T, Adshead J, Boustead G, Vasdev N. Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice. Clinical Genitourinary Cancer 2014, 13: e153-e158. PMID: 25510376, DOI: 10.1016/j.clgc.2014.11.006.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapy regimenNeoadjuvant chemotherapyPositive lymph nodesRadical cystectomyAdjuvant chemotherapyTreatment of patientsBladder cancerNodal diseaseLymph nodesIndication of adjuvant chemotherapyNode-positive bladder cancerPresence of disease progressionResponse to NACCancer CenterMuscle-invasive bladder cancerCycles of gemcitabineAdvanced bladder cancerPatient performance statusUro-oncologistsChemotherapy regimenPerformance statusLack of published evidenceDisease progressionChemotherapyPatients